Kanada - angleščina - Health Canada

auro pharma inc - acetylcysteine - solution - 200mg - acetylcysteine 200mg

Kanada - angleščina - Health Canada

eugia pharma inc. - acetylcysteine - solution - 200mg - acetylcysteine 200mg

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

omegapharm - acetylcysteine, quantity: 800 mg - solution - excipient ingredients: hydrochloric acid; water for injections; disodium edetate; sodium hydroxide - adjuvant therapy for patients with abnormal, viscid or inspissated mucous secretions in such conditions as: - chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung); - acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis); - pulmonary complications of cystic fibrosis; - pulmonary complications associated with surgery; - post-traumatic chest conditions; - atelectasis due to mucus obstruction; - tracheostomy care; - anaesthesia. acetylcysteine may also be used as an adjunct to diagnostic bronchial studies (bronchograms, bronchospirometry and bronchial wedge catheterisation).

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

omegapharm - acetylcysteine, quantity: 2000 mg - solution - excipient ingredients: disodium edetate; sodium hydroxide; water for injections; hydrochloric acid - adjuvant therapy for patients with abnormal, viscid or inspissated mucous secretions in such conditions as: - chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung); - acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis); - pulmonary complications of cystic fibrosis; - pulmonary complications associated with surgery; - post-traumatic chest conditions; - atelectasis due to mucus obstruction; - tracheostomy care; - anaesthesia. acetylcysteine may also be used as an adjunct to diagnostic bronchial studies (bronchograms, bronchospirometry and bronchial wedge catheterisation).

Kanada - angleščina - Health Canada

teligent ou - acetylcysteine - solution - 200mg - acetylcysteine 200mg - antidotes

Malezija - angleščina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sandoz products malaysia sdn. bhd. - acetylcysteine -

Malezija - angleščina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sandoz products malaysia sdn. bhd. - acetylcysteine -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - acetylcysteine, quantity: 2 g - injection, concentrated - excipient ingredients: water for injections; disodium edetate; sodium hydroxide - as an antidote for paracetamol poisoning: acetylcysteine injection concentrate is indicated in the treatment of paracetamol overdose to protect against hepatotoxicity.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

max health limited - acetylcysteine 20%{relative} - concentrate for infusion - 20% w/v - active: acetylcysteine 20%{relative} excipient: disodium edetate sodium hydroxide - n-acetylcysteine is indicated for the treatment of paracetamol overdose in patients: · who present within 15 hours after an acute overdose with a plasma paracetamol level on or above a line joining points of 150mg/l at 4h and 20mg/l at 15h (see nomogram below) or · who have taken more than 200mg/kg or 10g (whichever is less) of sustained release paracetamol or have one of two serum paracetamol levels taken four hours apart on or above a line joining points of 150mg/l at 4h and 20mg/l at 15h (see nomogram below) or · who have taken an acute overdose of paracetamol with opiates or medicines with anticholinergic effects and have one of two serum paracetamol levels taken four hours apart on or above a line joining points of 150mg/l at 4h and 20mg/l at 15h (see nomogram below) or · where there is any doubt over the time of an acute overdose, irrespective of plasma paracetamol level or · who present more than 15 hours after an overdose with abnormal liver biochemistry (inr >1.3 and/or alt>150) or fulminant hepatic failure or · who have taken a staggered overdose irrespective of plasma paracetamol level. staggered is defined as an overdose of 200mg/kg or 10g (whichever is less) over a single 24 hour period or 150mg/kg of 6g (whichever is less) per 24 hour period for at least 48 hours.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - acetylcysteine 200 mg/ml - concentrate for injection - 2 g/10ml - active: acetylcysteine 200 mg/ml excipient: disodium edetate dihydrate sodium hydroxide 5 m: 14.557 - 43.671 mg/ml sodium hydroxide water for injection - n-acetylcysteine is indicated for the treatment of paracetamol overdose in patients: - who present within 8 hours after an acute overdose of immediate-release paracetamol, with a serum paracetamol level on or over the nomogram line, or - who present more than 8 hours after an acute overdose of immediate-release paracetamol, or - who have ingested >= 200 milligrams/kg or >= 10 g (whichever is less) of modified-release paracetamol, or - who have ingested < 200 milligrams/kg and < 10 g of modified-release paracetamol, with serum paracetamol level over the nomogram line, or - who have ingested >= 200 milligrams/kg or >=10 g (whichever is less) of paracetamol over a single 24 hour period, and have an alt >=50 u/l or serum paracetamol concentration >=20 milligrams/l (132 micromol/l), or - who have ingested >=300 milligrams/kg or >=12 g (whichever is less) of paracetamol over a single 48 hour period, and have an alt >=50 u/l or serum paracetamol concentration >=20 milligrams/l (132 micromol/l), or - who have ingested the equivalent or more of a daily therapeutic dose of paracetamol per day for more than 48 hours and also have abdominal pain or nausea or vomiting, and have an alt >=50 u/l or serum paracetamol concentration >=20 milligrams/l (132 micromol/l), or - where there is any doubt over the time of an acute overdose, irrespective of serum paracetamol level, or - where serum paracetamol concentration is >=150 milligrams/l 4 hours post-ingestion in children less than 6 years of age.